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Background: This laboratory study compared the efficacy of Bravecto™ (fluralaner), formulated as a chewable
tablet, with the efficacy of Advocate® (imidacloprid/moxidectin), formulated for topical administration, against
naturally acquired generalized demodicosis in dogs.
Methods: Sixteen dogs, all diagnosed with generalized demodectic mange, were randomly allocated to two equal
groups. Bravecto™ chewable tablets were administered once orally at a minimum dose of 25 mg fluralaner/kg body
weight to one group of dogs, while the second group was treated topically on three occasions at 28-day intervals
with Advocate® at a minimum dose of 10 mg imidacloprid/kg body weight and 2.5 mg moxidectin/kg body weight.
Mites were counted in skin scrapings and demodectic lesions were evaluated on each dog before treatment and at
28-day intervals thereafter over a 12 week study period. Deep skin scrapings (~4 cm2) were made from the same five
sites on each dog at each subsequent examination.
Results: After single oral administration of Bravecto™ chewable tablets, mite numbers in skin scrapings were reduced
by 99.8% on Day 28 and by 100% on Days 56 and 84. Mite numbers in the dogs treated topically on three occasions at
28-day intervals with Advocate® were reduced by 98.0% on Day 28, by 96.5% on Day 56 and by 94.7% on Day 84.
Statistically significantly (P ≤ 0.05) fewer mites were found on Days 56 and 84 on the Bravecto™ treated dogs
compared to Advocate® treated dogs. A marked decrease was observed in the occurrence of erythematous patches,
crusts, casts and scales in the dogs treated with Bravecto™ and in the occurrence of erythematous patches in the dogs
treated with Advocate®. With the exception of one dog in each treated group, all dogs exhibited hair regrowth≥ 90%
at the end of the study in comparison with their hair-coat at study start.
Conclusions: Single oral administration of Bravecto™ chewable tablets is highly effective against generalized
demodicosis, with no mites detectable at 56 and 84 days following treatment. In comparison, Advocate®, administered
three times at 28-day intervals, is also highly effective against generalized demodicosis, but most dogs still harboured
mites at all assessment time points. Both treatments resulted in a marked reduction of skin lesions and increase of hair
re-growth 12 weeks after the initial treatment.
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Historically the only follicular mite considered to infest
dogs is Demodex canis [1], but two other mites have
subsequently been described. Desch and Hillier [2]
described Demodex injai, a mite that is considerably
longer than D. canis, while Tamura et al. [3] described a
mite that is considerably shorter than D. canis, but
failed to name it. In the literature this mite is now usu-
ally referred to as Demodex cornei. The three species
differ in length as described by Izdebska and Fryderyk
[4] with reference to average values. For D. canis adult
female mites measured 226.0 μm and the males
195.2 μm. Adult female D. injai measured 330.9 μm and
the males 371.8 μm. For D. cornei adult female mites
measured 139.4 μm and the males 120.8 μm. Various
molecular studies have been carried out to determine
the specific identities of the three mites. Based on the
results obtained from the mitochondrial markers 16S
rDNA and Cytochrome Oxidase I (COI) for the three
morphotypes of D. canis, De Rojas et al. [5] concluded
that they are polymorphs of the same species. On the
other hand phylogenetic analysis of the three species,
based on partial sequences of mitochondrial 16S rDNA,
led Sastre et al. [6] to propose that D. canis and D. injai
are valid separate species and D. cornei a morphological
variant of D. canis. A year later similar analyses per-
formed by Milosevic et al. [7] confirmed that D. injai is
a valid species. It is clear that further studies are
required to ascertain the specific status of the mite
referred to as D. cornei.
Demodex spp. mites (D. canis, D. injai, and D. cornei)
are normal commensals of the dog’s skin parasitising
within the sebaceous glands connected to the hair folli-
cles. Should their numbers increase dramatically, they
are capable of producing a disease known as canine
demodicosis or demodectic mange. Canine demodicosis
is an inflammatory parasitic skin disease that can be
classified as localized or generalized according to the
extent of the lesions. Localized demodicosis occurs as
only small areas of alopecia, most commonly on the face
and the forelegs. It is a benign disease and most cases
resolve spontaneously within six to eight weeks. Demo-
dicosis is considered generalized when five or more
areas on the body are affected, or pododemodicosis is
observed on two or more feet, or when an entire body
region is involved [8,9]. Demodicosis can also be catego-
rized as either juvenile (dogs up to 18 months of age),
adult onset (dogs generally older than four years of age
with no previous history of disease), or chronic general-
ized (persisting disease for at least six months) [10,11].
Susceptibility of dogs to infestations with Demodex spp.
and to progression of the clinical disease are influenced
by numerous factors including (listed in decreasing
order of importance): immune status which may beaffected by debilitating diseases, endoparasitism, breed,
age as well as nutritional or hormonal status, other
immunological disorders such as genetic defects and
alteration of the skin’s biochemistry and structure [12].
Although D. canis remains the most common species/
morphotype encountered in demodicosis, moderate alope-
cia, and greasy seborrhoeic dermatitis along the dorsal
trunk of dogs has been associated with increased numbers
of D. injai [13]. Moreover, bilateral ceruminous otitis in a
beagle, of which D. injai was the cause, has been described
[7]. D. cornei would appear to be an inhabitant of
the host’s stratum corneum [5], and Shipstone [11]
mentions that D. cornei has been found in association
with a generalised, pruritic, scaly dermatitis, with the
mites present in the surface scale.
Chronic generalized demodicosis is a frustrating and
difficult skin disease to treat [14-16]. In dogs that are
otherwise healthy, the generalized form of the disease is
unlikely to resolve without therapy [10]. Therapeutic
options that are currently available include amitraz,
ivermectin, milbemycin oxime and moxidectin, mostly
to be given at multiple occasions for periods of three
months or more [16-18]. To be effective, these treatment
regimens require high owner compliance over an ex-
tended period of time.
The active ingredient of Bravecto™, fluralaner, is a
novel, long-acting systemic insecticide and acaricide be-
longing to the isoxazoline class of parasiticides with
selective inhibition of arthropod γ–aminobutyric acid-
and L–glutamate-gated chloride channels [19]. In field
studies involving naturally infested dogs, a single oral
administration of Bravecto™, formulated as a chewable
tablet, proved to be > 99% effective against fleas and ticks
at each measured time-point over a period of 12 weeks
following treatment [20]. The dogs in these studies were
variably infested with at least four tick species, including
ticks belonging to the Rhipicephalus sanguineus group,
Ixodes hexagonus, Ixodes ricinus and Dermacentor reti-
culatus. In a simulated home environment a single oral
administration of Bravecto™ formulated as chewable tab-
lets was > 99% effective against the flea Ctenocephalides
felis, at every time-point measured over a period of
12 weeks following treatment [21]. In a laboratory study
designed to detect the speed of kill of Bravecto™ chew-
able tablets against laboratory infestations of the tick
I. ricinus on dogs, acaricidal efficacy was 89.6% at
4 hours, 97.9% at 8 hours and 100% at 12 and 24 hours
after treatment [22]. An even faster onset of killing activ-
ity starting at 1 hour after oral administration of
Bravecto™ chewable tablets was observed in dogs experi-
mentally infested with C. felis flea [23]. The aim of the
current study was to determine a) the efficacy of flurala-
ner against Demodex spp. mites and b) to show efficacy
duration over 12 weeks following single oral treatment
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In the present study, Bravecto™ administered as chew-
able tablets on a single occasion was the test product
and Advocate®, administered three times at 28-day in-
tervals was included as a positive control. This made it
possible to compare the long term efficacy of 12 weeks
of a single oral treatment with Bravecto™ chewable
tablets against the efficacy of Advocate® administered at
a 28-day interval according to the product label.
The study was designed as a parallel group, blinded,
randomized, single centre, and positive controlled effi-
cacy study. The study was conducted in accordance with
the FDA Code of Federal Regulations: Good Laboratory
Practice for Nonclinical Laboratory Studies 2009 [24],
and all procedures were in compliance with South
African National Standard “SANS 10386:2008: The care
and use of animals for scientific purposes” [25]. The
protocol was submitted to the ClinVet animal ethics
committee that authorized the conduct of the study.
The test system was the individual dog. Dogs with nat-
ural infestations of Demodex spp. mites and presenting
clinical signs of generalized demodicosis, e.g. erythema,
hair loss, comedones, follicular casts and crusts were en-
rolled, with consent from their owners, in the study and
were returned to their owners on completion of the
animal phase. Dogs included in the study were mostly
mongrels and of both sexes, older than 12 months,
weighed between 3.5 and 13.7 kg, and except for clinical
signs of generalized demodicosis, the dogs were healthy
and as far as could be determined the dogs had not been
treated with a glucocorticoid or any product with a
miticidal effect for at least 12 weeks prior to inclusion.
Additional requirements for inclusion were that deep
skin scrapings performed before treatment had to be
positive for Demodex spp. mites.
Sixteen dogs (7 male and 9 female), ranked within sex
in descending order of individual pre-treatment mite
counts were included in the study and allocated to two
equal groups. Each dog was housed individually for the
duration of the study in an indoor/outdoor run, without
contact between animals, and was fed once a day ac-
cording to the food manufacturer’s recommendations.
Potable municipal water was available ad libitum.
Each dog was acclimatized to the housing and main-
tenance conditions for at least 14 days before treatment.
As a precautionary measure all dogs were treated sub-
cutaneously with an antibiotic (cefovecin), appropriate
for the treatment of pyoderma on Days −14, −1, 13 and27. Additionally, on Days −14 and 27, deep skin biopsies
were taken from each dog after sedation. The biopsies
indicated that exudative pyoderma was present in two
dogs in each group on Day −14 and that it had cleared
by Day 27. Chronic dermatitis, epidermal acanthosis and
hyperkeratosis was present and unchanged in all dogs
on both occasions. No inflammatory cells or bacteria
were observed in the Day 27 biopsies and antimicrobial
therapy was discontinued. Twice during acclimatization
(Day −14 and Day −1) and on Days 27/28, 56 and 84
after treatment each dog was clinically examined by a
veterinarian.
The dogs were weighed on a calibrated and verified
electronic scale on Days −2, 13, 27, 41, 55, 69 and 84 for
dose calculation for treatment, for the use of sedatives
for skin scrapings and to document the body weight dur-
ing the study period. General health observations were
performed daily throughout the complete study period.
Treatment
On Day 0, dogs of one group were treated once orally
with Bravecto™ chewable tablets (fluralaner, 13.64% w/w),
based on the dog’s individual body weight, to achieve a
minimum dose of 25 mg/kg body weight and an efficacy
over 12 weeks following treatment. The tablet(s) was
(were) administered 20 (±10) minutes after food had been
offered by placement in the back of the oral cavity over
the tongue to initiate swallowing. Also on Day 0, commer-
cially available Advocate® (imidacloprid, 10%/moxidectin,
2.5% w/v) was administered topically to the other group of
dogs (positive controls) according to the product label.
Due to the 28 days efficacy duration of Advocate®, these
dogs were re-treated on Day 28 and 56. With the dog in a
standing position, the coat was parted until the skin was
visible and the Advocate® was administered directly onto
the skin. Both treated groups were observed prior to treat-
ment and again hourly for 4 hours after treatment of the
last animal, for possible adverse events. Personnel per-
forming the post-treatment observations were blinded
with respect to the treatment.
Mite assessments
Deep skin scrapings (~4 cm2), in which the skin was
squeezed and scraped until capillary oozing was seen, were
made from five sites on each dog on Days −4, 28, 56 and
84. Skin scrapings of the dogs treated with Advocate® were
performed on Day 28 and Day 56, before the second or
third treatment was applied, respectively. The same sites
and/or sites of new lesions were scraped at each subse-
quent examination. Each scraping was transferred to a
separate labelled microscope slide containing mineral oil
and was examined under a stereomicroscope for the
presence of Demodex spp. mites. The numbers of mites
counted in each scraping were recorded separately.
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The clinical signs and the extent of demodectic lesions
on each dog were assessed on the days when skin scrap-
ings were made, and recorded on a standardised form.
The following parameters were assessed and sketched
on a silhouette (left and right hand side) for each dog:
body areas exhibiting erythema; body areas covered by
casts, scales and crusts; body areas with hair loss. A
semi-quantitative assessment of hair re-growth was per-
formed, comparing hair coat before, within and after
the 12 weeks study duration and assessed as percentage
hair re-growth (0-50%, 50-90% or > 90%) defined as
estimated percentage of hair cover growth compared to
baseline total hairless area as assessed prior to vete-
rinary product administration. Colour photographs
illustrating the extent of lesions and their resolution
were taken of each dog on Day −4 and subsequently at
approximately monthly intervals up to Day 84 after
treatment.
Efficacy evaluation
The primary assessment variable in the study was the
decrease in total number of mites counted in skin scrap-
ings following treatment.
Efficacy was calculated using geometric means with
Abbott’s formula:
Efficacy %ð Þ ¼ Mpre – Mpostð Þ=Mpre x 100
where Mpre was the mean number of pre-treatment mite
counts, and Mpost the mean number of post-treatment
mite counts.Table 1 Geometric mean reductions in Demodex spp. mite co
topically on three occasions at 28-day intervals with Advocat
Study days Study groups B
−4 Meana mite counts (n) 4
Count range (n) 4
28 Meana mite counts (n) 0
Count range (n) 0
Efficacy (%) 9
56 Meana mite counts (n) 0
Count range (n) N
Efficacy (%) 1
84 Meana mite counts (n) 0
Count range (n) N
Efficacy (%) 1
aGeometric mean.
bMite counts calculated without one dog, which was euthanized on Day 59.
cNot applicable.Additionally, the groups were compared using an
ANOVA with a treatment effect after a logarithmic
transformation on the mite (count + 1) data, for each
study day.
On Day 50 one of the dogs in the group treated with
Advocate® developed severe oedema of the left hind leg
and prepuce and the swelling did not dissipate with anti-
biotic, diuretic and corticosteroid treatment. The dog
was removed from the study on Day 59, sedated and
upon laparotomy a large nodular tumour compatible
with malignant lymphoma was found attached to the
ventral spine, and the dog was euthanised during
surgery. The results pertaining to this dog until Day 56,
before its exclusion from the study on Day 59, have been
included with those of the other dogs in the group
treated with Advocate®.
Results
No adverse event considered to be related to oral treat-
ment with Bravecto™ chewable tablets or topical treat-
ment with Advocate® was observed in any dog.
Treatment with Bravecto™ chewable tablets resulted
in a reduction of the mean mite number present in skin
scrapings of 99.8% on Day 28, and of 100% on Days 56
and 84 after treatment. The treatment with Advocate®
resulted in a reduction of the mean mite number
present in skin scrapings of 98.0% on Day 28, of 96.4%
on Day 56, and of 94.7% on Day 84. Statistically sig-
nificantly (P ≤ 0.05) fewer mites were found on the
Bravecto™ treated dogs compared to Advocate® treated
dogs (Table 1).
The occurrence of erythematous patches on the dogs
treated once orally with Bravecto™ chewable tablets was














Table 2 Reduction in the occurrence of dermatologic
changes in dogs with generalized demodicosis after
treatment with either Bravecto™ or Advocate®
Bravecto™: occurrence of lesions on days before and after treatment
(dogs were treated on Day 0: number of dogs/number of dogs per
group)
Clinical sign Day −4 Day 28 Day 56 Day 84
Erythematous
patches
62.5% (5/8) 37.5% (3/8) 12.5% (1/8) 12.5% (1/8)
Crusts, casts
or scales
100% (8/8) 62.5% (5/8) 62.5% (5/8) 12.5% (1/8)
Advocate®; occurrence of lesions on days before and after initial
treatment (dogs were treated on Days 0, 28 and 56a: number of
dogs/number of dogs per group)
Clinical sign Day −4 Day 28 Day 56 Day 84
Erythematous
patches
87.5% (7/8) 50% (4/8) 0% (0/8) 0% (0/7)b
Crusts, casts
or scales
100% (8/8) 100% (8/8) 37.5% (3/8) 42.9% (3/7)b
aSkin assessments were performed before treatment.
bOn day 59 one dog had to be euthanized due to the presence of a malign
tumour in the stomach.
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ing initiation of treatment. The occurrence of crusts,
casts or scales was reduced from 100% (8/8) prior
to treatment to 12.5% (1/8) 12 weeks following initi-
ation of treatment. In comparison, the occurrence of
erythematous patches on dogs treated three times at a
28-day interval with Advocate® was reduced from
87.5% (7/8) to 0% (0/8) and the occurrence of crusts,
casts and scales was reduced from 100% (8/8) to 42.9%
(3/7) (Table 2).
Hair re-growth compared to the proportion of the
body area covered by hair prior to treatment is sum-
marized in Table 3. By Days 56 and 84 after initi-
ation of treatment, hair re-growth on the majority of
dogs in both groups exceeded the hair-coat of the
dogs by 90% compared with the pre-treatment as-
sessment (Figure 1).
The body weight of every dog increased similarly in




(number of dogs/number of dogs per group)
0-50% 50-90% >90%
28 3/8 1/8 4/8
56 0/8 1/8 7/8
84 0/8 1/8 7/8
aPercentage hair re-growth defined as estimated percentage of hair cover growth c
product administration.
bDogs were treated once orally on Day 0.
cDogs were treated topically on Day 0, on Day 28 and again on Day 56. Hair assess
dOn day 59 one dog had to be euthanized due to the presence of a malign tumouDiscussion
A single oral administration of Bravecto™ chewable
tablets to dogs with naturally acquired generalized
demodicosis resulted in significantly lower mean mite
counts 56 and 84 days after treatment and a corres-
pondingly greater efficacy at each time period com-
pared to three successive treatments with Advocate® at
an interval of 28 days. No mites were present in the
skin scrapings of the dogs 56 or 84 days after treatment
with BravectoTM chewable tablets, while a few mites
were still present in skin scrapings 56 (mite average:
18.5) and 84 (mite average: 25.6) days after the initial
treatment with Advocate®.
Reduction of mite counts was consistent with reduc-
tion in the extent and severity of the skin changes.
Both groups of dogs showed resolution of the associ-
ated dermatologic signs with steady improvement over
the 12 week treatment period. More Bravecto™ treated
dogs had resolution of crusts, casts and scales and
showed hair re-growth, while none of the Advocate®
treated dogs had erythema at the assessment time
point Day 84.
A problem frequently encountered with the treatment
of demodicosis in dogs is the inability to ensure that a
dog is absolutely free from mites after completion of a
specific treatment regimen and re-infestation can be
detected months after a treatment that was initially
considered to be successful [15,16]. The present results
are, however, encouraging that the administration of
Bravecto™ chewable tablets offers the potential to pro-
vide sustained control of demodex mite infestations in
susceptible dogs for at least three months after a single
treatment.
Owner compliance can be an important factor in treat-
ment success when multiple doses of a treatment spread
over a long period of time are required in order to
achieve a satisfactory outcome. Bravecto™ administered
once as chewable tablets is not only effective against
Demodex spp. mites on dogs but remains effective for
12 weeks following treatment. Moreover, it is effective
for the same period of time against ticks and fleas thatmange after treatment with Bravecto™ or Advocate®
percent hair re-growtha
Advocate®c





ompared to baseline total hairless area as assessed prior to veterinary
ments were performed before treatment.
r in the stomach.
Figure 1 Example of hair re-growth in a dog suffering from
generalized demodicosis pre-treatment (a) and 12 weeks after
initiation of treatment (b).
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fore, the single administration may help to reduce the
risk of treatment failure as a consequence of poor owner
compliance with treatment recommendations.
Bravecto™ chewable tablets have proved to be safe for
use in dogs at five times the recommended therapeutic
dose [26]. It is also safe to use in breeding, pregnant and
lactating dogs. With this in mind it could prove to be an
effective prophylactic intervention against the transmis-
sion of Demodex spp. mites from a post-parturient bitch
to her new-born pups aiding in the prevention and con-
trol of demodicosis in all its forms on the following gen-
eration of dogs.
Conclusions
Single oral administration of Bravecto™ chewable tablets
is highly effective against generalized demodicosis, with
no mites detectable at 56 and 84 days following treat-
ment. In comparison, Advocate®, administered three
times at 28-day intervals, is also highly effective against
generalized demodicosis, but most dogs still harbouredmites at all assessment time points. Both treatments re-
sulted in a marked reduction of skin lesions and increase
of hair re-growth 12 weeks after the initial treatment.
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